UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center - Awakn Life Sciences (OTC:AWKNF), Compass Pathways (NASDAQ:CMPS)

The U.K. Medicines and Healthcare Regulatory Agency (MHRA) has green-lighted two separate Phase 3 trials conducted by Compass Pathways (NASDAQ: CMPS) for Treatment-Resistant Depression and Awakn Life Sciences (OTCMKTS: AWKNF) for Severe Alcohol Use Disorder (SAUD).

Related Keywords

Exeter ,Devon ,United Kingdom ,London ,City Of ,Kabir Nath ,Anthony Tennyson ,James Rucker ,Allan Young ,Centre For Mental Health Research ,University Of Exeter ,Care Research ,Psychology Neuroscience At King College London ,Institute Of Psychiatry ,Health Research Authority ,National Institute For Health ,Awakn Life Sciences Corp ,Psychoactive Trials Group ,Healthcare Regulatory Agency ,Research Council ,Treatment Resistant Depression ,Awakn Life ,Severe Alcohol Use Disorder ,Mental Health Research ,South London ,College London ,Maudsley Hospital ,Academic Psychiatry ,Psychoactive Trials ,Regulatory And Ethical Approval For Phase ,Trial For ,Awakn Life Sciences ,National Institute ,Medical Research Council ,